Effects of SGLT2i (empagliflozin) in vivo therapy on complications in streptozotocin induced type 1 diabetes mellitus in Wistar rats with emphasis on antioxidant and antiinflammatory properties, suppression of systemic oxidative stress, inflammation, hyperglycemic damage and endothelial dysfunction by SGLT2 inhibition.